Hugel Inc., a leading global medical aesthetics company, said on Monday it had hosted a launch event of Letybo last week at Shangri-La Jakarta in Indonesia, the second-largest medical aesthetics market in Southeast Asia, to promote the clinical efficacy of the botulinum toxin.
The event comprised online and on-site lectures on techniques and trends of Letybo treatment. The lectures were led by Dr. Konstantin Frank, a plastic surgery resident at Ocean Clinic, Marbella in Spain, and medical aesthetics industry leaders in Indonesia.
Prior to the launch event, Hugel conducted a hands-on workshop on the safe and effective treatment of botulinum toxin for local doctors. Dr. Frank delivered an anatomy lecture on Letybo injection for Asians and performed live demonstrations for around 350 healthcare and medical professionals.
“We are pleased to have launched our premium botulinum toxin product Letybo in Indonesia, Southeast Asia’s second-largest medical aesthetics market after Thailand. Hugel will continue to engage with local practitioners through seminars and workshops for promotion of Letybo’s prowess,” a Hugel official said.
About Hugel
Established in 2001, Hugel is a leading global medical aesthetics company that manufactures injectables for skin rejuvenation such as botulinum toxin, hyaluronic acid fillers and skin boosters as well as absorbable sutures and cosmetics products. The company is the only South Korean supplier to the world’s three largest botulinum toxin markets, the US, China and Europe. It exports medical aesthetic products and devices to around 70 countries and operates eight global subsidiaries in the US, Australia, Canada, Taiwan, China, Hong Kong and Singapore.
(Photo caption: Hugel and its Indonesian partner Parvus host a launch event of botulinum toxin Letybo at Shangri-La Jakarta)
